Artiva Biotherapeutics (ARTV) Profit After Tax (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Profit After Tax data on file, last reported at -$23.6 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 16.38% year-over-year to -$23.6 million in Q1 2026; TTM through Mar 2026 was -$87.0 million, a 20.46% decrease from a year earlier, with the FY2025 full-year figure at -$83.6 million, down 27.08% from the prior year.
• Profit After Tax for Q1 2026 stood at -$23.6 million, down from -$20.5 million in the prior quarter.
• Over the last five years, Profit After Tax for ARTV reached as high as $11.4 million in Q3 2023 and fell as low as -$23.6 million in Q1 2026.
• Historically, Profit After Tax has averaged -$15.4 million across 4 years, with a median of -$17.7 million in 2024.
• Across the five-year window, Profit After Tax tumbled 252.95% in 2024 and retreated 16.38% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$12.3 million in 2023, then sank by 34.99% to -$16.6 million in 2024, then retreated by 24.02% to -$20.5 million in 2025, then retreated by 15.08% to -$23.6 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$23.6 million in Q1 2026, -$20.5 million in Q4 2025, and -$21.5 million in Q3 2025.